A CLEAR OPPORTUNITY
OcuNeo Therapeutics was founded to bring innovation to patients with rare ophthalmic diseases. Operating in stealth, OcuNeo develops first-in-class therapies for conditions affecting fewer than 200,000 patients in the U.S.
Our doctor-led team combines clinical insight, cutting-edge science, and patient-centered design, accelerating solutions for diseases historically ignored by conventional pharma.
Why Now?
Recent advances in translational science and streamlined regulatory pathways create an unprecedented window for high-impact ophthalmic innovation.
Diseases we work on:
Various ocular rare diseases
Leadership
Physician-founded leadership guiding clinically informed innovation.
Impact
Millions of patients worldwide live with rare and complex eye diseases. While some therapies exist, they often fall short, leaving patients with ongoing vision loss, discomfort, and diminished quality of life. At OcuNeo, we are committed to changing that. Every program we advance is designed to deliver the best possible therapies, restoring vision, improving daily function, and giving patients hope where current treatments fail. By focusing on diseases overlooked by conventional pharma, we aim to create breakthroughs that truly transform patient outcomes.
OCUNEO THERAPEUTICS 